PD-L1 Inhibitors in NSCLC: Precision, Personalization, and Practice Impact

Meeting Objectives:

• • Evaluate how histology, PD-L1 expression level, and disease burden influence the treatment selection in squamous and non-squamous NSCLC. 
  • Differentiate between PD-L1 inhibitors based on trial populations, design, and real-world applicability to support evidence-based decision-making. 
  • Apply best practices for managing immune-related adverse events, updating order sets, and integrating liquid biopsy results to guide patient-specific immunotherapy decisions.